FDA Grants Accelerated Approval to Brukinsa Plus Gazyva for Relapsed or Refractory Follicular Lymphoma

BeiGene’s Brukinsa is a small molecule Bruton’s tyrosine kinase inhibitor indicated as a monotherapy and in combination with other treatments for various B-cell malignancies.

Source link
#FDA #Grants #Accelerated #Approval #Brukinsa #Gazyva #Relapsed #Refractory #Follicular #Lymphoma